Aging-related early changes in markers of ventricular and matrix remodeling after reperfused st-segment elevation myocardial infarction in the canine model: Effect of early therapy with an angiotensin II type 1 receptor blocker

Circulation

Volumn 122, Issue 4, 2010, Pages 341-351

  Jugdutt, Bodh I ^a,b   Jelani, Anwar ^a   Palaniyappan, Ariv ^b   Idikio, Halliday ^c   Uweira, Richard E ^d   Menon, Vijay ^a   Jugdutt, Catherine E ^a  

^a Cardiology Division   (Canada)

^b Cardiovascular Research Group   (Canada)

^c Laboratory Medicine and Health Sciences   (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

Author keywords

aging; metalloproteinases; myocardial infarction; remodeling; reperfusion injury

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CANDESARTAN; CYTOKINE; GELATINASE A; GELATINASE B; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; MATRIX METALLOPROTEINASE 17; METALLOPROTEINASE; OSTEOPONTIN; PLACEBO; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; TISSUE INHIBITOR OF METALLOPROTEINASE 3;

AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DETERIORATION; DOG; EXTRACELLULAR MATRIX; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE BLOOD FLOW; HEART VENTRICLE REMODELING; HEMODYNAMICS; IMMUNOBLOTTING; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REPERFUSION INJURY; ST SEGMENT ELEVATION; SYSTOLE; TWO DIMENSIONAL ECHOCARDIOGRAPHY; ZYMOGRAPHY;

AGING; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; APOPTOSIS; BENZIMIDAZOLES; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; DOGS; ECHOCARDIOGRAPHY; IMMUNOBLOTTING; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; PLACEBOS; POLYMERASE CHAIN REACTION; REPERFUSION INJURY; RNA; SYSTOLE; TETRAZOLES;

EID: 77955175733     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.110.948190     Document Type: Article

References (43)

1. Pfeffer MA, Braunwald E. Ventricular remodelling after myocardial infarction. Circulation. 1990;81:1161-1172.
2. Jugdutt BI. Identification of patients prone to infarct expansion by the degree of regional shape distortion on an early two-dimensional echocar-diogram after myocardial infarction. Clin Cardiol. 1990;13:28-40.
3. St John Sutton M, Pfeffer MA, Moye L, Plappert T, Rouleau JL, Lamas G, Rouleau J, Parker JO, Arnold MO, Sussex B, Braunwald E. Cardiovascular death and left ventricular remodeling two years after myocardial infarction: baseline predictors and impact of long-term use of captopril: information from the Survival and Ventricular Enlargement (SAVE) trial. Circulation. 1997;96:3294-3299.
4. Alexander KP, Newby LK, Armstrong PW, Cannon CP, Gibler WB, Rich MW, Van de Werf F, White HD, Weaver WD, Naylor MD, Gore JM, Krumholz HM, Ohman EM, for the American Heart Association Council on Clinical Cardiology and Society of Geriatric Cardiology. Acute coronary care in the elderly, part II: ST-segment-elevation myocardial infarction: a scientific statement for healthcare professionals from the American Heart Association Council for Clinical Cardiology. Circulation. 2007;115: 2570-2589.
5. Jugdutt BI. Aging and remodeling during healing of the wounded heart: current therapies and novel drug targets. Curr Drug Targets. 2008;9: 325-344.
6. Bolognese L, Neskovic AN, Parodi G, Cerisano G, Buonamici P, Santoro GM, Antoniucci D. Left ventricular remodeling after primary coronary angioplasty: patterns of left ventricular dilation and long-term prognostic implications. Circulation. 2002;106:2351-2357.
7. Reimer KA, Jennings RB. The "wavefront phenomenon" of myocardial ischemic cell death, II: transmural progression of necrosis within the framework of ischemic bed size (myocardium at risk) and collateral flow. Lab Invest. 1979;40:633-644.
8. Kloner RA, Ellis SG, Lange R, Braunwald E. Studies of experimental coronary artery reperfusion: effects on infarct size, myocardial function, biochemistry, ultrastructure and microvascular damage. Circulation. 1983;68(suppl):I-8-I-15.
9. Ohno M, Takemura G, Ohno A. "Apoptotic" myocytes in infarct area in rabbit hearts may be oncotic myocytes with DNA fragmentation: analysis, by immunogold electron microscopy combined with in situ nick end-labeling. Circulation. 1998;98:1422-1430.
10. Matsumura K, Jeremy RW, Schaper J, Becker LC. Progression of myocardial necrosis during reperfusion of ischemic myocardium. Circulation. 1998;97:795-804.
11. Zhao MJ, Zhang H, Robinson TF, Factor SM, Sonnenblick EH, Eng C. Profound structural alterations of the extracellular collagen matrix in postischemic dysfunctional ("stunned") but viable myocardium. J Am Coll Cardiol. 1987;10:1322-1334.
12. Jugdutt BI. Ventricular remodeling post-infarction and the extracellular collagen matrix: when is enough enough? Circulation. 2003;108: 1395-1403.
13. Sawicki G, Menon V, Jugdutt BI. Improved balance between TIMP-3 and MMP-9 after regional myocardial ischemia-reperfusion during AT1 receptor blockade. J Card Fail. 2004;10:442-449.
14. Heymans S, Luttun A, Nuyens D, Theilmeier G, Creemers E, Moons L, Dyspersin GD, Cleutjens JP, Shipley M, Angellilo A, Levi M, Nübe O, Baker A, Keshet E, Lupu F, Herbert JM, Smits JF, Shapiro SD, Baes M, Borgers M, Collen D, Daemen MJ, Carmeliet P. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med. 1999;5:1135-1142.
15. Jugdutt BI, Tang SB, Khan MI, Basualdo CA. Functional impact of remodeling during healing after non-Q wave versus Q wave anterior myocardial infarction in the dog. J Am Coll Cardiol. 1992;20:722-731.
16. Hudson MP, Armstrong PW, Ruzyllo W, Brum J, Cusmano L, Krzeski P, Lyon R, Quinones M, Theroux P, Sydlowski D, Kim HE, Garcia MJ, Jaber WA, Weaver WD. Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial. J Am Coll Cardiol. 2006;48:15-20.
17. Jugdutt BI, Palaniyappan A, Uwiera RRE, Idikio H. Role of healing-specific-matricellular proteins and metalloproteinases in age-related enhanced early remodeling after reperfused STEMI in dogs. Mol Cell Biochem. 2009;322:25-36.
18. 2, and matrix metalloproteinases. J Clin Invest. 1997;99:894-900.
19. Schneeberger S, Hautz T, Wahl SM, Brandacher G, Sucher R, Steinmassl O, Steinmassl P, Wright CD, Obrist P, Werner ER, Mark W, Troppmair J, Margreiter R, Amberger A. The effect of secretory leukocyte protease inhibitor (SLPI) on ischemia-reperfusion injury in cardiac transplantation. Am J Transplant. 2008;8:773-782.
20. Fedak PW, Maravec CS, McCarthy PM, Altamentova SM, Wong AP, Skrtic M, Verma S, Weisel RD, Li RK. Altered expression of disintegrin metalloproteinases and their inhibitor in human dilated cardiomyopathy. Circulation. 2006;113:238-245.
21. Heymes C, Swynghedauw B, Chevalier B. Activation of angiotensinogen and angiotensin-converting enzyme gene expression in the left ventricle of senescent rats. Circulation. 1994;90:1328-1333.
22. Jugdutt BI, Xu Y, Balghith M, Menon V. Cardioprotective effects of angiotensin II type 1 receptor blockade with candesartan after reperfused myocardial infarction: role of angiotensin II type 2 receptor. J Renin Angiotensin Aldosterone Syst. 2001;2:S162-S166.
23. Ford WR, Khan MI, Jugdutt BI. Effect of the novel angiotensin II type 1 receptor antagonist L-158,809 on acute infarct expansion and acute anterior myocardial infarction in the dog. Can J Cardiol. 1998;14:73-80.
24. Sawicki G, Jugdutt BI. Valsartan reverses post-translational modifications of the S-subunit of ATP synthase during in vivo canine reperfused myocardial infarction. Proteomics. 2007;7:2100-2110.
25. Palaniyappan A, Idikio H, Uwiera R, Jugdutt BI. Comparison of vasopep-tidase inhibitor omapatrilat and angiotensin receptor blocker candesartan on extracellular matrix, myeloperoxidase, cytokines and ventricular remodeling during healing after reperfused myocardial infarction. Mol Cell Biochem. 2008;321:9-22.
26. Kowallik P, Schulz R, Guth BD, Schade A, Paffhausen W, Gross R, Heusch G. Measurement of regional myocardial blood flow with multiple colored microspheres. Circulation. 1991;83:974-982.
27. Liu X, Huang Y, Pokreisz P, Vermeersch P, Marsboom G, Swinnen M, Verbeken E, Santos J, Pellens M, Gillijns H, Van de Werf F, Bloch KD, Janssens S. Nitric oxide inhalation improves microvascular flow and decreases infarction size after myocardial ischemia and reperfusion. J Am Coll Cardiol. 2007;50:808-817.
28. Becker LC, Jeremy RW, Schaper J, Schaper W. Ultrastructural assessment of myocardial necrosis occurring during ischemia and 3-h reperfusion in the dog. Am J Physiol. 1999;277:H243-H252.
29. Reimer KA, Jennings RB. The changing anatomic reference base of evolving myocardial infarction: underestimation of experimental infarct size due to tissue edema, hemorrhage, and acute inflammation. Circulation. 1979;60: 866-876.
30. Jugdutt BI, Becker LC, Hutchins GM. Early changes in collateral blood flow during myocardial infarction in conscious dogs. Am J Physiol. 1979;237:H371-H380.
31. Jugdutt BI. Myocardial salvage by intravenous nitroglycerin in conscious dogs: loss of beneficial effect with marked nitroglycerin-induced hypotension. Circulation. 1983;68:673-684.
32. Ambrosio G, Weisman HF, Mannisi JA, Becker LC. Progressive impairment of regional myocardial perfusion after initial restoration of postischemic blood flow. Circulation. 1989;80:1846-1861.
33. Reffelmann T, Hale SL, Dow JS, Kloner RA. No-reflow phenomenon persists long-term after ischemia/reperfusion in the rat and predicts infarct expansion. Circulation. 2003;108:2911-2917.
34. 1 receptor blockade alters metabolic, functional and structural proteins after reperfused myocardial infarction: detection using proteomics. Mol Cell Biochem. 2004;263:179-188.
35. Boengler K, Schulz R, Heusch G. Loss of cardioprotection with ageing. Cardiovasc Res. 2009;83:247-261.
36. de Cavanagh EM, Ferder M, Inserra F, Ferder L. Angiotensin II, mitochondria, cytoskeletal, and extracellular matrix connections: an inte-grating viewpoint. Am J Physiol Heart Circ Physiol. 2009;296: H550-H558.
37. Wang W, Sawicki G, Schulz R. Peroxynitrite-induced myocardial injury is mediated through matrix metalloproteinase-2. Cardiovasc Res. 2002; 53:165-174.
38. Siwik DA, Pagano PJ, Colucci WS. Oxidative stress regulates collagen synthesis and matrix metalloproteinase activity in cardiac fibroblasts. Am J Physiol Cell Physiol. 2001;280:C53-C60.
39. Ridnour LA, Windhausen AN, Isenberg JS, Yeung N, Thomas DD, Vitek MP, Roberts DD, Wink DA. Nitric oxide regulates matrix metalloproteinases-9 activity by guanylyl-cyclase-dependent and-independent pathways. Proc Natl Acad Sci USA. 2007;104:16898-16903.
40. Siwik DA, Colucci WS. Regulation of matrix metalloproteinases by cytokines and reactive oxygen/nitrogen species in the myocardium. Heart Fail Rev. 2004;9:43-51.
41. Smookler DS, Mohammed FF, Kassiri Z, Duncan GS, Mak TW, Khokha R. Tissue inhibitor of metalloproteinase 3 regulates TNF-dependent systemic inflammation. J Immunol. 2006;176:721-725.
42. Fedak PWM, Smookler DS, Kassiri Z, Ohno N, Leco KJ, Verma S, Mickle DAG, Watson KL, Hojilla CV, Cruz W, Weisel RD, Li R, Khokha R. TIMP-3 deficiency leads to dilated cardiomyopathy. Circulation. 2004;110:2401-2409.
43. Chen H, Saldeen T, Mehta JL. TGF-beta 1 attenuates myocardial ische-mia-reperfusion injury via inhibition of upregulation of MMP-1. Am J Physiol Heart Circ Physiol. 2003;234:H1612-H1617.